Homepage / Technology / How a party drug could become the next blockbuster antidepression treatment
Amazon says this Prime Day was its biggest shopping event ever Kudlow says President Trump is 'so dissatisfied' with China trade talks that he is keeping the pressure on As stocks regain their footing, an ominous warning looms Goldman Sachs downgrades Clorox to sell, says valuation is 'unsustainably high' How Satya Nadella has spurred a tripling of Microsoft's stock price in just over four years Kudlow says economic growth could top 4% for 'a quarter or two,' more tax cuts could be coming The one chart that explains Netflix’s stunning comeback US housing starts plunge 12% in June to a nine-month low Aerospace titans Boeing and Airbus top $110 billion in orders at Farnborough Target uses Prime Day to its advantage, logging its 'biggest online shopping day' so far this year Billionaire Marc Lasry sees bitcoin reaching up to $40,000 as it becomes more mainstream and easier to trade These are the 10 US airports where you're most likely to be hacked Amazon shares slightly higher as investors await Prime Day results Wreck of Russian warship found, believed to hold gold worth $130 billion A bullish ‘phenomenon’ in bond market is weeks away from fading, top credit strategist says Stocks making the biggest moves premarket: MS, GOOGL, TXN, UAL, NFLX & more Twitter shares up 50% since late April means most upside priced in, analyst says in downgrade EU fines Google $5 billion over Android antitrust abuse Mortgage applications fall 2.5% as buyers struggle to find affordable homes America may not have the tools to counter the next financial crisis, warn Bernanke, Geithner and Paulson Investors are getting spooked as the risk of a no-deal Brexit rises EU expected to fine Google $5 billion over Android antitrust abuse Ex-FBI chief James Comey urges Americans to vote for Democrats in midterm elections Elon Musk apologizes to British cave diver following baseless 'pedo guy' claim Disney, Comcast and Fox: All you need to know about one of the biggest media battles ever Xiaomi shares notch new high after Hong Kong, mainland China stock exchanges reach agreement The trade war is complicating China's efforts to fix its economy European markets set for a strong open amid earnings; Google in focus Hedge fund billionaire Einhorn places sixth in major poker tournament The biggest spender of political ads on Facebook? President Trump Asian stocks poised to gain after Fed's Powell gives upbeat comments; dollar firmer Stocks are setting up to break to new highs Not all FAANG stocks are created equal EU ruling may be too little, too late to stop Google's mobile dominance Cramer explains how Netflix's stock managed to taper its drop after disappointing on earnings Airbnb condemns New York City's 'bellhop politics,' threatens legal retaliation Amazon sellers say they were unfairly suspended right before Prime Day, and now have two bad choices Investor explains why 'duller' tech stocks can have better returns than 'high-flying' tech names Elon Musk is 'thin-skinned and short-tempered,' says tech VC Texas Instruments CEO Brian Crutcher resigns for violating code of conduct Google Cloud Platform fixes issues that took down Spotify, Snapchat and other popular sites Uber exec: We want to become the 'one stop' transportation app 'What a dumb hearing,' says Democrat as Congress grills tech companies on conservative bias Amazon shares rebound, report says Prime Day sales jumped 89 percent in first 12 hours of the event How to put your medical history on your iPhone in less than 5 minutes Investment chief: Watch these two big events in 2018 Even with Netflix slowing, the market rally is likely not over Cramer: Netflix subscriber weakness debunks the 'sky's the limit' theory on the stock Netflix is looking at watch time as a new area of growth, but the competition is stiff Why Nobel laureate Richard Thaler follows Warren Buffett's advice to avoid bitcoin Rolls-Royce is developing tiny 'cockroach' robots to crawl in and fix airplane engines After Netflix plunge, Wall Street analysts forecast just tame returns ahead for the once high-flying FANG group Roku shares rise after analyst raises streaming video company's price target due to customer growth China is investing 9 times more into Europe than into North America, report reveals Amazon says US Prime Day sales 'so far bigger than ever' as glitch is resolved Netflix is on pace for its worst day in two years US lumber producers see huge opportunity, rush to expand San Francisco to consider tax on companies to help homeless Homebuilder sentiment, still high, stalls as tariffs, labor and land drive up costs Powell backs more rate hikes as economy growing 'considerably stronger' Netflix history is filled with big stock declines – like today – followed by bigger rebounds Intel shares get downgraded by Evercore ISI due to rising competition from Nvidia, AMD Petco aims to reinvent the pet store with something you can't buy online Genetic testing is coming of age, but for consumers it's buyer beware Tech 'FAANG' was the most-crowded trade in the world heading into the Netflix implosion, survey shows Netflix weak subscriber growth may indicate a 'maturity wall' that could whack the stock even more: Analyst This chart may be predicting the bull market's demise Wall Street says Netflix's stock plunge is a ‘compelling’ buying opportunity because the streaming giant ‘never misses twice’ Tesla sinks after Musk tweets, again Boeing announces new division devoted to flying taxis Stocks making the biggest move premarket: NFLX, UNH, GS, AMZN, WMT & more Deutsche Bank downgrades Netflix, but says big subscriber miss is not 'thesis changing' IBM is experimenting with a cryptocurrency that’s pegged to the US dollar North Korea and Zimbabwe: A friendship explained Virgin Galactic spinoff Orbit to launch rockets from the UK with space deal Artificial intelligence will create more jobs than it destroys? That’s what PwC says ‘Treasonous’ Trump and ‘Putin’s poodle:' Scathing headlines follow the Trump-Putin summit China’s fintech companies offer ‘enormous’ opportunity, investment manager says Trump's performance at summit with Putin was 'unprecedented,' experts say Walmart and Microsoft link up on cloud technology as they both battle Amazon European stocks seen mixed amid earnings; Fed’s Powell to address Congress How I knew I should quit my day job and run my start-up full-time: Viral website founder China's stocks have been trounced, but the trade war may ultimately be good news for those shares Billionaire tech investor Peter Thiel bets on crypto start-up Block.one Asian shares subdued open after mixed close on Wall Street; energy stocks under pressure Amazon cloud hits snags after Amazon Prime Day downtime Netflix isn't doomed by one quarter unless people start questioning the long-term investor thesis Tech stocks set to sink on Tuesday after rough evening for ‘FANG’ Netflix plummets after missing big on subscriber growth This wristband lets humans control machines with their minds The U.S. has a rocky history convincing Russia to extradite computer criminals Amazon suffers glitches at the start of Prime Day Jeff Bezos is now the richest man in modern history 'The United States has been foolish': Read Trump and Putin's full exchange Goldman Sachs recommends these 5 highly profitable companies — including Nvidia — to combat rising inflation Goldman Sachs releases 'tactical' stock picks for this earnings season Three red flags for Netflix ahead of its earnings report The bond market may be raising recession fears, but don't expect one anytime soon Cramer: Banks are 'making fortunes' but are still as hated as they were during the financial crisis Putin told Trump at summit: Russia never meddled in US election

Technology

How a party drug could become the next blockbuster antidepression treatment

As a social worker with 30 years’ experience working in hospice care, Christina Ingenito expected to face death gracefully when her time came. But when a breast cancer diagnosis at 59 left this once ebullient woman “severely clinically depressed” — her words — she turned to an unusual research project for help.

In 2016, Ingenito became one of 18 subjects in the first-ever FDA-cleared study to explore the therapeutic effects of MDMA — commonly known as ecstasy — on people with life-threatening illnesses who are suffering from depression. After four standard (i.e., sober) therapy sessions with the two psychologists leading the study, Ingenito embarked on three “medicine journeys,” as she calls them: marathon eight-hour therapy sessions fueled by capsules of MDMA.

“Incredible” is how she describes the experience now. “From the very first moment that I felt the medicine in my body, it radically transformed all the trauma that I had been holding, not only from the diagnosis but previously from my life as well. My anxiety is gone; the depression is gone; my life force is back.” Today she is free from both cancer and depression.

Depression now affects 16 million Americans and 350 million adults worldwide, according to the NIMH, making it one of the most common disabilities in the world. But even with more than 20 antidepressants approved by the FDA over the past 60 years, many people still struggle with the condition: One-third of Americans simply don’t respond to any of the currently available medicines, studies say, and there hasn’t been a significant breakthrough in decades. As the years of desperation mount, doctors are finding themselves turning to new and unexpected sources for the next big antidepression drug.

Though there is no shortage of antidepression drugs currently available, analysts believe there is still plenty of opportunity in the nearly $17 billion global market.

The notion that a “party drug” like MDMA could be used for more than recreation may have been out of fashion for many years, but it’s not a new idea. Before it was outlawed in the 1960s, LSD showed promise as a treatment for depression and alcoholism. Dr. Phillip Wolfson, an author of Ingenito’s study, was one of several mental health professionals experimenting with MDMA as a therapy aid in the early 1980s before it was outlawed. But a combination of prohibition and social stigma rendered it nearly impossible to get government permission, much less funding, to perform any sort of research with such drugs.

Now a handful of studies — and the persistent researchers behind them — are pointing to a future where drugs like LSD, MDMA, ketamine and psilocybin (the active ingredient in hallucinogenic mushrooms) could find a second life not just as therapeutic aids but as potential blockbusters.

More from Modern Medicine:
Scientists invent a pen that identifies cancer in 10 seconds
Scientists narrow down the risk factors that can cause autism
Insurers, doctors battle over new heart disease drugs

“MDMA has a blockbuster aspect in many, many areas,” said Dr. Wolfson in a telephone interview. “It could be used for PTSD, depression, couples’ work, relationship work and probably OCD.” The evidence, he claims, is in the studies now being published.

Though results of Ingenito’s study are still being analyzed, preliminary data suggests the MDMA sessions dramatically alleviated depression in the subjects. That follows an earlier study that tested MDMA as a treatment for PTSD in which 80 percent of subjects no longer suffered from the condition after just two sessions.

Early studies with psilocybin have been similarly encouraging. In a 2016 NYU study looking at whether the drug could alleviate anxiety and depression in cancer patients, more than 80 percent of subjects reported significant improvements. A smaller 2012 study yielded similar results.

Ketamine — which goes by the street name Special K — has been studied more than most illicit drugs, thanks to its legal status in the United States as a tranquilizer (usually for animals). And results have been so encouraging that both Allergen and Johnson & Johnson currently have ketamine-inspired antidepressants in late-stage clinical trials.

Of course, ketamine and MDMA are powerful drugs with serious side effects that would need to be managed. Ketamine’s paralyzing effect can be so powerful, it’s often classified as a date-rape drug, and users sometimes asphyxiate because they can’t clear their own airwaves. MDMA can induce symptoms resembling a panic attack — sweating, nausea, chills, involuntary teeth clenching — and is occasionally associated with heat stroke.

Due to the risks, there is a clinical study under way at Stanford University to test if ketamine acts like an opioid.

Promising as the research on some illicit drugs is, scientists caution that many of these treatments are still years away from commercial availability, and the testing itself is, in many cases, still in its infancy.

For example, a team of researchers in the U.K. last year became the first ever to produce images of the human brain on LSD — a remarkable fact, considering how widely the drug has been consumed over the past 50 years. But the obstacles to working with the drug were simply too great, said Professor David Nutt, a neuropsychopharmacologist at Imperial College and an author of the study. “The illegal status of LSD meant that researchers were scared, and the costs of complying with the regulations were prohibitive, and governments wouldn’t fund the research because the drugs were illegal.”

Still, the results of the scans strongly suggested that LSD could help treat depression in much the way psilocybin does. “It switches off regions of the brain that are overactive in depression,” Nutt said. It also disrupts communication between certain sections of the brain, producing an “ego dissolution” that helps users feel more connected to the world around them.

Such results are going a long way toward easing the path for researchers who want to explore these drugs. As is the existence of groups like MAPS (Multidisciplinary Association for Psychedelic Studies), which has helped secure private funding for much of the research on these drugs — a notoriously difficult endeavor given the stigma surrounding them.

Of course, MAPS is not the first group to advocate for the legal use of psychedelics. And hopes of a breakthrough in the area seem to arise every decade or so, suggesting the path to FDA approval may still be a long, arduous one.

But Dr. Wolfson, who has watched the enthusiasm for researching psychedelic drugs rise and fall over the decades, says he’s never seen the surge of interest like he is seeing now. “Interest is peaking,” said Dr. Wolfson, but “it hasn’t peaked yet.”

— By Douglas Quenqua, special to CNBC.com

Source: Tech CNBC
How a party drug could become the next blockbuster antidepression treatment

Comments are closed.